Endothelin Antagonists and the Quest for a New Therapeutic Option for Resistant Hypertension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
Lancet 2022 Nov 04;[EPub Ahead of Print], MP Schlaich, M Bellet, MA Weber, P Danaietash, GL Bakris, JM Flack, RF Dreier, M Sassi-Sayadi, LP Haskell, K Narkiewicz, JG WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.